```
d his

         (FILE 'HOME' ENTERED AT 09:38:14 ON 16 AUG 2007)

         FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 09:38:27 ON 16
         AUG 2007
L1          40711 S URINE AND (MASS SPECTRO?)
L2           1224 S L1 AND ELECTROPHORESIS?
L3             74 S L2 AND DIGEST?
L4             38 S L3 AND PEPTIDE?
L5             28 DUPLICATE REMOVE L4 (10 DUPLICATES REMOVED)
L6             17 S L5 AND PD<2004

      =>
```

```
d his

        (FILE 'HOME' ENTERED AT 09:38:14 ON 16 AUG 2007)

        FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 09:38:27 ON 16
        AUG 2007
L1        40711 S URINE AND (MASS SPECTRO?)
L2         1224 S L1 AND ELECTROPHORESIS?
L3           74 S L2 AND DIGEST?
L4           38 S L3 AND PEPTIDE?
L5           28 DUPLICATE REMOVE L4 (10 DUPLICATES REMOVED)
L6           17 S L5 AND PD<2004

=>
```

AB   Provided are mammalian secreted and non-secreted diabetes
    mediating proteins, including protective and deleterious diabetes
    -mediating proteins, as well as polynucleotides encoding same, drug
    screening methods for identifying a test compound capable of altering the
    expression of a diabetes-mediating protein, and methods of
    preventing or ameliorating diabetes by administering a compound
    capable of altering the expression of a diabetes-mediating
    protein. The proteins were identified by monitoring IL-1β induced
    protein changes in diabetes prone mammalian islets of Langerhans
    using two-dimensional gel electrophoresis. Protein spots that
    significantly changed expression levels after exposure to IL-1β were
    cut out of the gels and subjected to MALDI mass
    spectrometry. Eighty-two significantly changed protein spots were
    detected. Pos. identification was obtained for a total of 45 different
    proteins from 51 of the 82 spots.
ST   mammalian diabetes protein diagnosis therapy; interleukin 1beta
    diabetes protein expression; electrophoresis
    mass spectrometry diabetes protein
IT   Progesterone receptors
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
    unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
    (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
    (Preparation); USES (Uses)
       (25-Dx; mammalian diabetes-mediating proteins identification
      for diagnosis and therapy)
IT   Keratins
    RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN
    (Biosynthetic preparation); BSU (Biological study, unclassified); DGN
    (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP
    (Preparation); USES (Uses)
       (8; mammalian diabetes-mediating proteins identification for
      diagnosis and therapy)
IT   Heterogeneous nuclear ribonucleoproteins
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
    unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
    (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
    (Preparation); USES (Uses)
       (A2/B1; mammalian diabetes-mediating proteins identification
      for diagnosis and therapy)
IT   Proteins
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
    unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
    (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
    (Preparation); USES (Uses)
       (ERP 29 (endoplasmic reticulum protein 29) precursor; mammalian
      diabetes-mediating proteins identification for diagnosis and
      therapy)
IT   Proteins
    RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN
    (Biosynthetic preparation); BSU (Biological study, unclassified); DGN
    (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP
    (Preparation); USES (Uses)
       (GRP78 (glucose-regulated protein, 78 kDa); mammalian diabetes
      -mediating proteins identification for diagnosis and therapy)
IT   Transcription factors
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
    unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
    (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
    (Preparation); USES (Uses)
       (IE-1 (immediate-early, 1), cytomegalovirus; mammalian diabetes
      -mediating proteins identification for diagnosis and therapy)
IT   Pancreatic islet of Langerhans
       (IL-1β-induced protein changes in diabetes-prone;
      mammalian diabetes-mediating proteins identification for

diagnosis and therapy)
IT   Ribosomal proteins
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (L11, 60; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Heterogeneous nuclear ribonucleoproteins
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (M4, deletion mutant; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Proteins
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (TOAD 64; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Anion channel
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (VDAC (voltage-dependent anion channel); mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Proteins
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (amyloid β- peptide binding; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Pancreas
   (anal. of tissue sample of; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Animal tissue
Lymph
Saliva
   (anal. of; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Chemical compounds
   (binding to diabetes-mediating proteins; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Nucleic acids
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
   (binding to diabetes-mediating proteins; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Proteins
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (craniofacial development protein 1; mammalian diabetes-mediating proteins identification for diagnosis and therapy)
IT   Proteins
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN

(Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
  (diabetes-mediating; mammalian diabetes-mediating
  proteins identification for diagnosis and therapy)
IT Translation initiation factors
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
  (eIF-4A, NUK like; mammalian diabetes-mediating proteins
  identification for diagnosis and therapy)
IT Proteins
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
  (endoplasmins, precursor; mammalian diabetes-mediating
  proteins identification for diagnosis and therapy)
IT Polynucleotides
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
  (for diabetes-mediating proteins; mammalian diabetes
  -mediating proteins identification for diagnosis and therapy)
IT Agglutinins and Lectins
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
  (galectin-3; mammalian diabetes-mediating proteins
  identification for diagnosis and therapy)
IT Autoimmune disease
  (insulin-dependent diabetes mellitus; mammalian
  diabetes-mediating proteins identification for diagnosis and
  therapy)
IT Diabetes mellitus
  (insulin-dependent; mammalian diabetes-mediating proteins
  identification for diagnosis and therapy)
IT Antidiabetic agents
Blood analysis
  Diabetes mellitus
Diagnosis
Drug screening
Human
Immunoassay
Mammalia
Nucleic acid hybridization
Susceptibility (genetic)
Test kits
  Urine analysis
  (mammalian diabetes-mediating proteins identification for
  diagnosis and therapy)
IT Calreticulin
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
  (mammalian diabetes-mediating proteins identification for
  diagnosis and therapy)
IT Antibodies and Immunoglobulins

RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
   (monoclonal, to diabetes-mediating proteins; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Gene expression
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (of diabetes-mediating proteins; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Laser ionization mass spectrometry
   (photodesorption, matrix-assisted; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Laser desorption mass spectrometry
   (photoionization, matrix-assisted; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Gel electrophoresis
   (polyacrylamide; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Interleukin 1β
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
   (protein changes in diabetes-prone islets of Langerhans in response to; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Proteins
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (secretagogin; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
   (to diabetes-mediating proteins; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Gel electrophoresis
   (two-dimensional; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   Tubulins
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (β-, 5 chain; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   9001-59-6P, Pyruvate kinase
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (M2 isoenzyme; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   37318-49-3P, Protein disulfide isomerase
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (P5 precursor; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   9001-15-4P
     RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN
     (Biosynthetic preparation); BSU (Biological study, unclassified); DGN
     (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (b; mammalian diabetes-mediating proteins identification for
          diagnosis and therapy)
IT   9000-97-9P, Aspartate aminotransferase
     RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (cytosolic and mitochondrial precursor; mammalian diabetes
          -mediating proteins identification for diagnosis and therapy)
IT   9001-58-5P, Isocitrate dehydrogenase
     RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (isoform 2, mitochondrial; mammalian diabetes-mediating
          proteins identification for diagnosis and therapy)
IT   99676-46-7P, Kexin
     RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (isoforms 1 and 2; mammalian diabetes-mediating proteins
          identification for diagnosis and therapy)
IT   9001-05-2P, Catalase   9001-40-5P, Glucose-6-phosphate dehydrogenase
     RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPN
     (Biosynthetic preparation); BSU (Biological study, unclassified); DGN
     (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (mammalian diabetes-mediating proteins identification for
          diagnosis and therapy)
IT   9001-50-7P, Glyceraldehyde-3-phosphate dehydrogenase   9023-62-5P,
     Glutathione synthetase   9026-42-0P, Pyridoxal kinase   9027-80-9P,
     Adenosine phosphoribosyltransferase   9031-72-5P, Alcohol dehydrogenase
     9032-03-5P, 5-Aminoimidazole-4-carboxamide ribonucleotide
     formyltransferase   9037-67-6P, β-Alanine oxoglutarate
     aminotransferase   9079-67-8P, NADH dehydrogenase   37278-21-0P, UMP-CMP
     kinase   89700-37-8P, Carbonyl reductase
     RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (mammalian diabetes-mediating proteins identification for
          diagnosis and therapy)
IT   9001-64-3P, Malate dehydrogenase   9024-25-3P, Aconitate hydratase
     RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (mitochondrial precursor; mammalian diabetes-mediating
          proteins identification for diagnosis and therapy)
IT   9028-40-4P, L-3-Hydroxyacyl-CoA dehydrogenase   9037-14-3P,
     5-Aminolevulinate synthase
     RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
          (precursor; mammalian diabetes-mediating proteins
          identification for diagnosis and therapy)
IT   9000-83-3P, ATPase

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

    (proton-transporting, lysosomal (vascular protein pump) β polypeptide 56/58; mammalian diabetes-mediating proteins identification for diagnosis and therapy)

IT   37205-63-3P, ATP synthase

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

    (α chain precursor, mitochondrial; mammalian diabetes -mediating proteins identification for diagnosis and therapy)